The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

* Patients will be designated into one of two groups based upon the results of a FDG-PET scan. * A patient with a baseline positive scan will have serum drawn for baseline serum proteomics assessment then be treated with RAD001 daily for two weeks. On day 10-14, another FDG-PET scan and serum assessment will be performed. An optional bone marrow biopsy may also be done. On day 15, patients will enter the Phase I portion of the trial at the current enrolling dosage or if Phase I is completed patients will enter Phase II. * A patient that does not have a positive scan will enter directly into the Phase I trial or Phase II depending on which trial is currently enrolling. * Phase I trial patients will have weekly laboratory evaluations and clinical evaluation every three weeks. * Phase II trial patients will have laboratory evaluations on day one and day eight and clinical evaluation every three weeks. * The maximum duration of the trial is one year of therapy.